Hims & Hers Health Narrows 2026 Guidance After Q3 Results
Hims & Hers Health reported Q3 results below expectations on Nov. 9, reducing its 2026 revenue forecast to $3.13B-$3.15B and adjusting EBITDA guidance. Shares fell 14.92% to $22.12 by Nov. 10.
How this was made

The 30-second read
Why it matters
The earnings miss and guidance reduction triggered a sharp sell‑off, suggesting near‑term downside risk.
Market read
The news directly impacts HIMS stock and may influence sentiment toward the broader telehealth sector.
What to watch
Potential cost‑saving initiatives or upcoming product launches that could offset the revenue shortfall.
Background
Hims & Hers Health is a publicly traded telehealth provider that has been expanding its consumer health platform.
Ticker impact
Hims & Hers Health reported Q3 results that missed expectations and narrowed its 2026 revenue guidance to $3.13‑$3.15 B, causing the stock to fall 14.9%.
downward pressure as investors reprice lower 2026 outlook
The company lowered full‑year revenue guidance and its shares dropped nearly 15% on the news, indicating a strong negative reaction.
Market effects
Telehealth sector may face broader valuation pressure as guidance cuts raise concerns about demand and cost structure.
U.S. market sentiment could be slightly dampened, especially among health‑tech and digital‑health stocks.
Limited to U.S. investors; no immediate global macro impact.
Counterpoint
If the guidance cut reflects a temporary slowdown and the company can improve margins, the stock may be oversold.
Key entities
- companyHims & Hers Health
Telehealth provider that reported Q3 results and lowered 2026 guidance.




